

Amend the remaining claims and add new claims as follows:

11. (Amended) [The] A heterocyclic compound [of claim 10, wherein the compound of the formula (IIa) is] selected from the group consisting of:

[(1) N-(1-hexyl-5-carboxyethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,]

(1) N-(1-hexyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(2) N-(1-heptyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(3) N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(4) N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(5) N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(6) N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and

(7) N-(1-dodecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

[(8) N-(1-hexyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,

(9) N-(1-hexyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

Patent No. 6,063,806
Amdt. dated June 27, 2003
Re: Reissue of USP 6,063,806

(10) N-(1-heptyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,

(11) N-(1-heptyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(12) N-(1-octyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, and

(13) N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,]

or a pharmaceutically acceptable salt thereof.

17. (Amended) A pharmaceutical composition comprising an effective amount of a heterocyclic compound of claim [1] 11 or a pharmaceutically acceptable salt thereof.

Add new claims as follows:

20. (New) The heterocyclic compound of claim 11 wherein the compound is in the form of a pharmaceutically acceptable salt which is an acid addition salt with an acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid.

21. (New) The heterocyclic compound of claim 11, which is N-(1-hexyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

22. (New) The heterocyclic compound of claim 11, which is N-(1-heptyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

23. (New) The heterocyclic compound of claim 11, which is N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

24. (New) The heterocyclic compound of claim 11, which is N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

25. (New) The heterocyclic compound of claim 11, which is N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

26. (New) The heterocyclic compound of claim 11, which is N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

27. (New) The heterocyclic compound of claim 11, which is N-(1-dodecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmaceutically acceptable salt.

Patent No. 6,063,806
Amdt. dated June 27, 2003
Re: Reissue of USP 6,063,806

28. (New) The heterocyclic compound of claim 11, which is a hydrochloric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

29. (New) The heterocyclic compound of claim 11, which is a sulfuric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

30. (New) The heterocyclic compound of claim 11, which is a nitric acid addition salt of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.